Latest Virus-like particle Stories
QUEBEC CITY, Nov. 28, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG) (OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Mike Wanner, Executive Vice-President Operations, will be presenting at the 5(th) Annual LD MICRO Growth Conference. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles on December...
QUEBEC CITY, Nov. 21, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Andy Sheldon, President and Chief Executive Officer of Medicago, will be presenting at the 2012 Piper Jaffray Healthcare Conference. The conference is being held at the New York Palace Hotel in New York on...
- First Demonstration of Cross-Protection Against H2N2 Influenza and a Different H5N1 Strain - QUEBEC CITY, Nov. 20, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced results from an independent preclinical study on the cross-protection effects of Medicago's H5N1 VLP vaccine...
ITTIGEN, Switzerland, November 8, 2012 /PRNewswire/ -- - Patent already granted in Europe - Pevion Biotech AG today announced the launch of a new program called Defensomes, a platform for broad spectrum immune enhancement via mechanisms of innate immunity. The proprietary technology is derived from a vaccine platform with a solid safety track record comprising more than 80 million doses applied to humans to date. Defensomes offer opportunities for a wide range of...
QUEBEC CITY, Oct. 29, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Chief Scientific Officer and co-founder Dr. Louis-Philippe Vézina has been named as a recipient of the 2012 Prix du Quebec. The Prix du Quebec is the most prestigious award given by the Government of Québec...
-Progress made towards production of biosimilar products in tobacco plants- QUEBEC CITY and SAINT PAUL, MN, Oct. 4, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG) (OTCQX: MDCGF), ("Medicago") a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus Like Particles ("VLP"s), and Cellectis plant sciences, a US-based subsidiary of Cellectis Group (Alternext: ALCLS), ("Cellectis"), the...
Medicago to receive up to US$12 million in upfront and milestone payments as well as royalties QUEBEC CITY, Sept. 25, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the signing of a licensing agreement with Philip Morris Products SA ("PMP"), a subsidiary of Philip Morris...
QUEBEC CITY, Aug. 29, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG) (OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Mike Wanner, Executive Vice-President Operations, will be presenting at the 2012 Stifel Nicolaus Healthcare Conference. The conference is being held at The Four Seasons Hotel in Boston on September 5 and...
SEATTLE and QUEBEC CITY, Aug. 16, 2012 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they...
QUEBEC CITY, Aug. 14, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG, OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced its operational and financial results for the second quarter ended June 30, 2012. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. "In the second...
